AMRFX
Price
$58.76
Change
-$0.03 (-0.05%)
Updated
Sep 20 closing price
VIVAX
Price
$67.77
Change
-$0.06 (-0.09%)
Updated
Sep 20 closing price
Ad is loading...

AMRFX vs VIVAX

Header iconAMRFX vs VIVAX Comparison
Open Charts AMRFX vs VIVAXBanner chart's image
American Funds American Mutual F2
Price$58.76
Change-$0.03 (-0.05%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index I
Price$67.77
Change-$0.06 (-0.09%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
AMRFX vs VIVAX Comparison Chart
Loading...
VS
AMRFX vs. VIVAX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRFX is a Buy and VIVAX is a Buy.

FUNDAMENTALS
Fundamentals
VIVAX has more cash in the bank: 183B vs. AMRFX (105B). VIVAX (2.25) and AMRFX (2.16) have matching dividends . AMRFX was incepted earlier than VIVAX: AMRFX (16 years) vs VIVAX (32 years). AMRFX is a more actively managed with annual turnover of: 25.00 vs. VIVAX (10.00). AMRFX has a lower initial minimum investment than VIVAX: AMRFX (250) vs VIVAX (3000). VIVAX (23.98) and AMRFX (23.94) have marching annual gain over last year. VIVAX return over 5 years is better than : 55.44 vs. AMRFX (52.58).
AMRFXVIVAXAMRFX / VIVAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence16 years32 years-
Gain YTD16.85616.261104%
Front LoadN/AN/A-
Min. Initial Investment25030008%
Min. Initial Investment IRAN/AN/A-
Net Assets105B183B57%
Annual Yield % from dividends2.162.2596%
Returns for 1 year23.9423.98100%
Returns for 3 years25.5028.2890%
Returns for 5 years52.5855.4495%
Returns for 10 years77.86113.9568%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EOLS16.570.13
+0.79%
Evolus
CTRE30.32-0.23
-0.75%
CareTrust REIT
DKS212.52-1.81
-0.84%
Dick's Sporting Goods
TSBX0.63-0.04
-6.60%
Turnstone Biologics Corp
OBIO4.93-0.37
-6.98%
Orchestra BioMed Holdings